DelveInsight’s, “Hypertension Pipeline Insight, 2023,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Hypertension pipeline landscape. It covers the Hypertension pipeline drug profiles, including Hypertension clinical trials and nonclinical stage products. It also covers the Hypertension pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Hypertension Pipeline Report
To know more about the latest breakthrough in the Hypertension Treatment Landscape @ Hypertension Pipeline Outlook Report
Hypertension Overview
High blood pressure (BP), or hypertension, is defined by two levels by 2017 American College of Cardiology/American Heart Association (ACC/AHA) guidelines: (1) elevated BP, with a systolic pressure (SBP) between 120 and 129 mm Hg and diastolic pressure (DBP) less than 80 mm Hg, and (2) stage 1 hypertension, with an SBP of 130 to 139 mm Hg or a DBP of 80 to 89 mm Hg. Hypertension is the most common primary diagnosis in the United States. It affects approximately 86 million adults (≥20 years) in the United States and is a major risk factor for stroke, myocardial infarction, vascular disease, and chronic kidney disease. Hypertension is defined as a systolic blood pressure (SBP) of 140 mm Hg or more, or a diastolic blood pressure (DBP) of 90 mm Hg or more, or taking antihypertensive medication. Hypertension may be primary, which may develop as a result of environmental or genetic causes, or secondary, which has multiple etiologies, including renal, vascular, and endocrine causes. Primary or essential hypertension accounts for 90-95% of adult cases, and secondary hypertension accounts for 2-10% of cases. The evaluation of hypertension involves accurately measuring the patient’s blood pressure, performing a focused medical history and physical examination, and obtaining results of routine laboratory studies.
Recent Developmental Activities in the Hypertension Treatment Landscape
Learn more about the Hypertension Emerging Therapies @ Hypertension Ongoing Clinical Trials Analysis
Hypertension Emerging Drugs Profile
Firibastat: Quantum Genomics
The firibastat product (initially named QGC001 or RB150) is the first BAPAI drug candidate selected by Quantum Genomics. The product firibastat is a prodrug which releases the product EC33, a selective and specific inhibitor of Aminopeptidase A, in the brain, and thus prevents the production of Angiotensin III in the brain. Due to its unique mechanism of action, firibastat represents an alternative therapeutic approach that may interfere with the mechanisms involved in the genesis and maintenance of excessively high blood pressure in hypertensive patients, especially those with a particular hormonal profile, characterized by a lowered renin and high vasopressin concentration.
Baxdrostat (CIN-107): CinCor Pharma
Baxdrostat (CIN-107) selectively targets aldosterone synthase, which is encoded by the CYP11B2 gene. Importantly, it has low affinity for 11ß-hydroxylase, the enzyme responsible for cortisol synthesis, which is encoded by the CYP11B1 gene. In multiple preclinical in vivo studies, baxdrostat (CIN-107) significantly lowered aldosterone levels without affecting cortisol levels, across a wide range of doses. Similar observations were made in multiple Phase 1 clinical trials in healthy volunteers. Currently, it is in Phase II stage of clinical trial evaluation to treat Hypertension.
MLS-101: Mineralys Therapeutics
MLS-101 is a highly selective aldosterone synthase inhibitor designed to address elevated aldosterone, an underlying cause of hypertension prevalent in at least 25% of all hypertensive patients. MLS-101 has demonstrated excellent selectivity for the reduction of aldosterone without effecting other hormones like cortisol. MLS-101 selectivity holds the potential for targeted treatment of blood pressure in hypertension patients with elevated aldosterone production.
Zilebesiran (ALN-AGT): Alnylam Therapeutics
Zilebesiran (ALN-AGT01) is a subcutaneously administered, investigational RNAi therapeutic targeting angiotensinogen (AGT) in development for the treatment of hypertension in high unmet need populations. Zilebesiran utilizes the company’s Enhanced Stabilization Chemistry Plus (ESC+)-GalNAc delivery platform. Currently, it is in Phase II stage of clinical trial evaluation to treat Hypertension.
IONIS-AGT-LRx: Ionis Pharmaceuticals
IONIS-AGT-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of angiotensinogen to decrease blood pressure in patients with treatment resistant hypertension (TRH). Despite availability of generic antihypertensive agents, TRH is a major contributor to cardiovascular and renal disease. Inhibiting the renin-angiotensin-aldosterone system (RAAS) is a well-established method of treating hypertension and complications of hypertension. While angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are widely used, many patients with high blood pressure are not well controlled by these treatment options. Angiotensinogen, the target of IONIS-AGT-LRx, is upstream of ACE inhibitors and ARBs in the RAAS pathway. Therefore, reducing angiotensinogen levels has the potential to decrease blood pressure in patients whose blood pressure is not adequately controlled by currently available treatment options. Furthermore, inhibiting angiotensinogen, which is made in the liver, may maintain renal compensatory mechanisms, which could lead to fewer side effects compared to current standard of care.
Hypertension Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Hypertension. The companies which have their Hypertension drug candidates in the most advanced stage, i.e. phase III include, Reata Pharmaceuticals.
Discover more information about the Hypertension Unmet Needs, Market Drivers, and Barriers @ Hypertension Treatment Landscape
Scope of the HypertensionPipeline Report
Table of Content
For further information on the hypertension pipeline therapeutics, reach out to Hypertension Market Drivers and Barriers
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/